{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T20:47:16Z","timestamp":1786654036233,"version":"build-2736575974"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100017577","name":"Zhejiang Province Basic Public Welfare Research Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017577","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.bcp.2026.118215","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T23:00:25Z","timestamp":1783119625000},"page":"118215","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Design, synthesis, and biological evaluation of Combretastatin A4 dimers for the treatment of hepatocellular carcinoma"],"prefix":"10.1016","volume":"252","author":[{"given":"Yu-Jing","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai-Bing","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiu-Dan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Qi","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao-Yang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Ni","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Juan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Qing","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2026.118215_b0005","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0140-6736(22)01200-4","article-title":"Hepatocellular carcinoma","volume":"400","author":"Vogel","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2026.118215_b0010","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/35025220","article-title":"Angiogenesis in cancer and other diseases","volume":"407","author":"Carmeliet","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2026.118215_b0015","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/s41573-023-00671-z","article-title":"Targeting angiogenesis in oncology, ophthalmology and beyond","volume":"22","author":"Cao","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bcp.2026.118215_b0020","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2026.118215_b0025","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2026.118215_b0030","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41392-020-00264-x","article-title":"Targeted therapy for hepatocellular carcinoma","volume":"5","author":"Huang","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bcp.2026.118215_b0035","doi-asserted-by":"crossref","first-page":"8685","DOI":"10.1021\/acs.jmedchem.6b00463","article-title":"Blocking blood flow to solid tumors by destabilizing tubulin: an approach to targeting tumor growth","volume":"59","author":"P\u00e9rez-P\u00e9rez","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2026.118215_b0040","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S1470-2045(00)00224-2","article-title":"Targeting tumour vasculature: the development of combretastatin A4","volume":"2","author":"Griggs","year":"2001","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bcp.2026.118215_b0045","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.bioorg.2017.04.007","article-title":"Development of combretastatins as potent tubulin polymerization inhibitors","volume":"72","author":"Bukhari","year":"2017","journal-title":"Bioorganic Chem."},{"key":"10.1016\/j.bcp.2026.118215_b0050","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.3390\/ph18091330","article-title":"Synthesis, computational studies, and structural analysis of 1-(3,5-dimethoxyphenyl)azetidin-2-ones with antiproliferative activity in breast cancer and chemoresistant colon cancer","volume":"18","author":"Malebari","year":"2025","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bcp.2026.118215_b0055","doi-asserted-by":"crossref","first-page":"28139","DOI":"10.1038\/srep28139","article-title":"The anti-angiogenic effect and novel mechanisms of action of Combretastatin A-4","volume":"6","author":"Su","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2026.118215_b0060","first-page":"1399","article-title":"Mechanistic considerations in benzene physiological model development","volume":"104","author":"Medinsky","year":"1996","journal-title":"Environ. Health Perspect."},{"key":"10.1016\/j.bcp.2026.118215_b0065","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.cbi.2009.12.025","article-title":"The fate of benzene-oxide","volume":"184","author":"Monks","year":"2010","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.bcp.2026.118215_b0070","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jsbmb.2013.02.009","article-title":"Synthesis of combretastatin A4 analogues on steroidal framework and their anti-breast cancer activity","volume":"137","author":"Parihar","year":"2013","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.bcp.2026.118215_b0075","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.3390\/molecules25112560","article-title":"Combretastatins: an overview of structure, probable mechanisms of action and potential applications","volume":"25","author":"Karatoprak","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.bcp.2026.118215_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117021","article-title":"A novel life for antitumor combretastatins: recent developments of hybrids, prodrugs, combination therapies, and antibody-drug conjugates","volume":"281","author":"Fantacuzzi","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bcp.2026.118215_b0085","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1182\/blood-2004-11-4564","article-title":"An inducible caspase 9 safety switch for T-cell therapy","volume":"105","author":"Straathof","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2026.118215_b0090","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.jconrel.2020.07.036","article-title":"Dimeric prodrug-based nanomedicines for cancer therapy","volume":"326","author":"Li","year":"2020","journal-title":"J. Controlled Release"},{"key":"10.1016\/j.bcp.2026.118215_b0095","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1158\/1078-0432.CCR-11-3376","article-title":"Phase I trial of Combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer","volume":"18","author":"Nathan","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2026.118215_b0100","doi-asserted-by":"crossref","first-page":"887","DOI":"10.2174\/138955710792007196","article-title":"Targeted enzyme prodrug therapies","volume":"10","author":"Schellmann","year":"2010","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.bcp.2026.118215_b0105","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.163624","article-title":"Interfering with lipid metabolism through targeting CES1 sensitizes hepatocellular carcinoma for chemotherapy","volume":"8","author":"Li","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.bcp.2026.118215_b0110","first-page":"2605","article-title":"Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan","volume":"8","author":"Xu","year":"2002","journal-title":"Clin. Cancer Res. off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.bcp.2026.118215_b0115","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1021\/acs.jproteome.0c00787","article-title":"Potential regulatory role of human-carboxylesterase-1 glycosylation in liver cancer cell growth","volume":"19","author":"Na","year":"2020","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.bcp.2026.118215_b0120","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1124\/dmd.108.021428","article-title":"Expression of UGT1A and UGT2B mRNA in human normal tissues and various cell lines","volume":"36","author":"Nakamura","year":"2008","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2026.118215_b0125","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ejmech.2017.02.049","article-title":"\u03b2-Lactam analogues of combretastatin A-4 prevent metabolic inactivation by glucuronidation in chemoresistant HT-29 colon cancer cells","volume":"130","author":"Malebari","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bcp.2026.118215_b0130","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1021\/jp011755a","article-title":"Aqueous solubility\u2212molecular size relationships: a mechanistic case study using C10 - to C19 -alkanes","volume":"106","author":"Tolls","year":"2002","journal-title":"J. Phys. Chem. A"},{"key":"10.1016\/j.bcp.2026.118215_b0135","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1021\/acsmedchemlett.6b00451","article-title":"Systematic study of effects of structural modifications on the aqueous solubility of drug-like molecules","volume":"8","author":"Cisneros","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bcp.2026.118215_b0140","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.chembiol.2014.08.013","article-title":"Oral druggable space beyond the rule of 5: insights from drugs and clinical candidates","volume":"21","author":"Doak","year":"2014","journal-title":"Chem. Biol."},{"key":"10.1016\/j.bcp.2026.118215_b0145","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jconrel.2019.11.027","article-title":"Enabling P-glycoprotein inhibition in multidrug resistant cancer through the reverse targeting of a quinidine-PEG conjugate","volume":"317","author":"Snyder","year":"2020","journal-title":"J. Controlled Release"},{"key":"10.1016\/j.bcp.2026.118215_b0150","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1124\/dmd.113.053512","article-title":"In vitro drug metabolism by human carboxylesterase 1: focus on angiotensin-converting enzyme inhibitors","volume":"42","author":"Thomsen","year":"2014","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2026.118215_b0155","article-title":"Responsive ROS\u2010augmented prodrug hybridization nanoassemblies for multidimensionally synergitic treatment of hepatocellular carcinoma in cascade assaults","volume":"12","author":"Zeng","year":"2025","journal-title":"Adv. Sci."},{"key":"10.1016\/j.bcp.2026.118215_b0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40661-017-0058-5","article-title":"Clinical trial experience with CA4P anticancer therapy: focus on efficacy, cardiovascular adverse events, and hypertension management","volume":"5","author":"Grisham","year":"2018","journal-title":"Gynecol. Oncol. Res. Pract."},{"key":"10.1016\/j.bcp.2026.118215_b0165","doi-asserted-by":"crossref","first-page":"27525","DOI":"10.1021\/acsami.2c02103","article-title":"Implantable sandwich-like scaffold\/fiber composite spatiotemporally releasing Combretastatin A4 and doxorubicin for efficient inhibition of postoperative tumor recurrence","volume":"14","author":"Fang","year":"2022","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.bcp.2026.118215_b0170","doi-asserted-by":"crossref","first-page":"23746","DOI":"10.1021\/acsnano.5c03638","article-title":"Combretastatin A4-based albumin nanoparticles remodeling the tumor immune microenvironment to enhance T cell immunotherapy in colon cancer","volume":"19","author":"Wang","year":"2025","journal-title":"ACS Nano"},{"key":"10.1016\/j.bcp.2026.118215_b0175","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.2147\/IJN.S188971","article-title":"Liver-targeted liposomes for codelivery of curcumin and Combretastatin A4 phosphate: preparation, characterization, and antitumor effects","volume":"14","author":"Jiang","year":"2019","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.bcp.2026.118215_b0180","doi-asserted-by":"crossref","first-page":"18319","DOI":"10.1039\/D4NR01487A","article-title":"Lipid nanoparticles for enhancing oral bioavailability","volume":"16","author":"Gangavarapu","year":"2024","journal-title":"Nanoscale"},{"key":"10.1016\/j.bcp.2026.118215_b0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.114097","article-title":"Oral delivery of therapeutic peptides and proteins: technology landscape of lipid-based nanocarriers","volume":"182","author":"Haddadzadegan","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bcp.2026.118215_b0190","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s40122-023-00529-7","article-title":"Celecoxib oral solution and the benefits of self-microemulsifying drug delivery systems (SMEDDS) technology: a narrative review","volume":"12","author":"Silberstein","year":"2023","journal-title":"Pain Ther."},{"key":"10.1016\/j.bcp.2026.118215_b0195","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.jconrel.2022.03.043","article-title":"Strategies to improve the EPR effect: a mechanistic perspective and clinical translation","volume":"345","author":"Ikeda-Imafuku","year":"2022","journal-title":"J. Controlled Release"},{"key":"10.1016\/j.bcp.2026.118215_b0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114614","article-title":"The tumor EPR effect for cancer drug delivery: current status, limitations, and alternatives","volume":"191","author":"Sun","year":"2022","journal-title":"Adv. Drug Deliv. Rev."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000629522600554X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000629522600554X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T20:15:48Z","timestamp":1786652148000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000629522600554X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":40,"alternative-id":["S000629522600554X"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118215","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis, and biological evaluation of Combretastatin A4 dimers for the treatment of hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118215","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"118215"}}